IMA — ImageneBio, Inc.

—
Nasdaq · Health Care · Biotechnology · CIK 1835579 ·
Last close
$3.90
Market Cap
$48.58M
52W High
$7.89
52W Low
$3.01
ADV30
15,323
Next earnings
—
ImageneBio, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for patients with immunological, autoimmune and inflammatory diseases. Its lead product candidate includes IMG-007, a non-depleting anti-OX40 monoclonal antibody that binds to OX40 receptor on activated T cells to block receptor binding to OX40 ligand which is in Phase 1b/2a clinical trial. The company was formerly known as Ikena Oncology, Inc. and changed its name to ImageneBio, Inc. in July 2025. ImageneBio, Inc. is headquartered in San Diego, California.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Sep 2026 0 — -17,309,000 -15,620,000 142,541,000 84,853,000 14,403,000
Jun 2026 0 — -11,784,000 -10,178,000 152,045,000 94,677,000 9,971,000
Mar 2026 0 — -12,079,000 -10,619,000 136,682,000 76,048,000 13,355,000
Dec 2025 0 — -8,504,000 -6,908,000 152,976,000 94,532,000 19,837,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-40,612,000
Investing CF
$-2,535,000
Financing CF
$24,886,000
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-5.40
As of
2026-11-15

Balance + Analyst (yfinance extras)

Retained Earnings
$-266,470,000
Inventory
—
Receivables
$1,296,000
ST Investments
$41,744,000
EBIT TTM
$-49,676,000
Pretax Income TTM
$-43,555,000
Interest Exp TTM
—
Analysts
3

Yahoo Snapshot (yfinance, live)

Total Revenue
$0
EBITDA
$-58,366,500
Free Cash Flow
$-23,211,624
Enterprise Value
$-89,175,720
Total Cash
$136,152,992
Total Debt
$1,912,000
Shares Out
12,456,281
Trailing EPS
$-2.11
Book Value
$11.91
ROE
-82.7%
ROA
-43.1%
Div Yield
0.00%

Annual Trend (SEC EDGAR, last 3y)

Revenues vs Net Income (last 3y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 800,000 -48,451,000 -45,349,000 152,976,000 19,837,000 133,139,000 -47,844,000
Dec 2024 3,500,000 -37,000,000 -36,568,000 15,922,000 176,487,000 -160,565,000 -21,319,000
Dec 2023 7,962,000 -21,925,000 -21,148,000 31,245,000 157,353,000 -126,108,000 -18,233,000

TTM Snapshot

Revenues TTM
$800,000
NetIncome TTM
$-54,760,000
OpCashFlow TTM
—
Assets (Latest)
$152,045,000
Forward EPS
$-3.36

Peers — same industry

TickerNameMarket CapLastDaily %
INKT MiNK Therapeutics, Inc. $47.67M $9.28 —
SGMOQ SANGAMO THERAPEUTICS, INC $45.57M $0.11 —
OKYO OKYO Pharma Ltd $57.99M $1.11 —
PMCB PharmaCyte Biotech, Inc. $58.19M $5.42 —
ELOX Eloxx Pharmaceuticals, Inc. $40.34M $11.74 —

News headlines (Yahoo Finance, 1h cache)

ImageneBio Reports Third Quarter 2026 Financial Results
2026-11-09 21:05 · Yahoo
ImageneBio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-10-02 20:30 · Yahoo
ImageneBio to Participate in H.C. Wainwright 28th Annual Global Investment Conference in New York
2026-09-08 20:30 · Yahoo
ImageneBio Reports Second Quarter 2026 Financial Results
2026-08-05 12:00 · Yahoo
ImageneBio Appoints Matt Robbins as General Counsel
2026-07-07 11:00 · Yahoo
ImageneBio Announces $30 Million Private Placement
2026-04-13 11:00 · Yahoo
ImageneBio to Participate in 2026 Jefferies Global Healthcare Conference in New York
2026-05-27 20:30 · Yahoo
ImageneBio Reports First Quarter 2026 Financial Results and Provides IMG-007 Program Update
2026-05-07 20:05 · Yahoo
Imax announces $28M opening weekend for Amazon/MGM/s ‘Project Hail Mary’
2026-03-24 12:35 · Yahoo
ImageneBio Appoints Immunology Drug Development Veteran Dr. Ben Porter-Brown as Chief Medical Officer
2026-02-10 12:00 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.